Teva's Continued US Weakness Drags Down Q211 Results

BMI View: Teva's Q211 results are unimpressive but expected given the company's poor Q111 performance. However, BMI remains positive about the company's long-term future as austerity measures and rational prescriptions increase generic drugs sales in developed states and the company's revenues from Europe continue to grow rapidly. BMI believes that Teva's share price will outperform the BMI Pharma 20 Index in the later half of 2011.

To read the full article, please choose one of the following options: